The Oncology Institute, Inc. TOI Clinical trials & other — Other Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherOperatingIncome.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s clinical trials & other — other operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s clinical trials & other — other operating income?
- The Oncology Institute, Inc. (TOI) reported clinical trials & other — other operating income of $813K in Q1 2026.
- How has The Oncology Institute, Inc.'s clinical trials & other — other operating income changed year-over-year?
- The Oncology Institute, Inc.'s clinical trials & other — other operating income decreased by 54.2% year-over-year, from $1.77M to $813K.
- What is the long-term trend for The Oncology Institute, Inc.'s clinical trials & other — other operating income?
- Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s clinical trials & other — other operating income has grown at a -5.7% compound annual growth rate (CAGR), from $5.37M to $4.24M.
- What does clinical trials & other — other operating income mean?
- This metric captures revenue streams generated by the clinical trials and other segment that are ancillary to the primary patient care services. It reflects the segment's ability to diversify income through research partnerships, grants, or other non-core operational activities.